Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2.
Biomed Pharmacother
; 142: 111953, 2021 Oct.
Article
in English
| MEDLINE | ID: covidwho-1322006
ABSTRACT
Currently, there are over 230 different COVID-19 vaccines under development around the world. At least three decades of scientific development in RNA biology, immunology, structural biology, genetic engineering, chemical modification, and nanoparticle technologies allowed the accelerated development of fully synthetic messenger RNA (mRNA)-based vaccines within less than a year since the first report of a SARS-CoV-2 infection. mRNA-based vaccines have been shown to elicit broadly protective immune responses, with the added advantage of being amenable to rapid and flexible manufacturing processes. This review recapitulates current advances in engineering the first two SARS-CoV-2-spike-encoding nucleoside-modified mRNA vaccines, highlighting the strategies followed to potentiate their effectiveness and safety, thus facilitating an agile response to the current COVID-19 pandemic.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Biomedical Engineering
/
Drug Discovery
/
Drug Development
/
COVID-19 Vaccines
/
SARS-CoV-2
/
COVID-19
Type of study:
Prognostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Biomed Pharmacother
Year:
2021
Document Type:
Article
Affiliation country:
J.biopha.2021.111953
Similar
MEDLINE
...
LILACS
LIS